Literature DB >> 16507773

c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.

Jay L Hess1, Claudia B Bittner, Deniz T Zeisig, Christian Bach, Uta Fuchs, Arndt Borkhardt, Jon Frampton, Robert K Slany.   

Abstract

Abdominal-type HoxA genes in combination with Meis1 are well-documented on-cogenes in various leukemias but it is unclear how they exert their transforming function. Here we used a system of conditional transformation by an inducible mixed lineage leukemia-eleven-nineteen leukemia (MLL-ENL) oncoprotein to overexpress Hoxa9 and Meis1 in primary hematopoietic cells. Arrays identified c-Myb and a c-Myb target (Gstm1) among the genes with the strongest response to Hoxa9/Meis1. c-Myb overexpression was verified by Northern blot and quantitative reverse transcription-polymerase chain reaction (RT-PCR). Also MLL-ENL activated c-Myb through up-regulation of Hoxa9 and Meis1. Consequently, short-term suppression of c-Myb by small inhibitory RNA (siRNA) efficiently inhibited transformation by MLL-ENL but did not impair transformation by transcription factor E2A-hepatic leukemia factor (E2A-HLF). The anti c-Myb siRNA effect was abrogated by coexpression of a c-Myb derivative with a mutated siRNA target site. The introduction of a dominant-negative c-Myb mutant had a similar but weaker effect on MLL-ENL-mediated transformation. Hematopoietic precursors from mice homozygous for a hypo-morphic c-Myb allele were more severely affected and could be transformed neither by MLL-ENL nor by E2A-HLF. Ectopic expression of c-Myb induced a differentiation block but c-Myb alone was not transforming in a replating assay similar to Hoxa9/Meis1. These results suggest that c-Myb is essential but not sufficient for Hoxa9/Meis1 mediated transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507773      PMCID: PMC1895838          DOI: 10.1182/blood-2005-12-5014

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Authors:  Bernd B Zeisig; Tom Milne; María-Paz García-Cuéllar; Silke Schreiner; Mary-Ellen Martin; Uta Fuchs; Arndt Borkhardt; Sumit K Chanda; John Walker; Richard Soden; Jay L Hess; Robert K Slany
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia.

Authors:  H A Drabkin; C Parsy; K Ferguson; F Guilhot; L Lacotte; L Roy; C Zeng; A Baron; S P Hunger; M Varella-Garcia; R Gemmill; F Brizard; A Brizard; J Roche
Journal:  Leukemia       Date:  2002-02       Impact factor: 11.528

3.  Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny.

Authors:  Nicolas Pineault; Cheryl D Helgason; H Jeffrey Lawrence; R Keith Humphries
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

4.  Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia.

Authors:  K R Calvo; P S Knoepfler; D B Sykes; M P Pasillas; M P Kamps
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

5.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.

Authors:  Scott A Armstrong; Jane E Staunton; Lewis B Silverman; Rob Pieters; Monique L den Boer; Mark D Minden; Stephen E Sallan; Eric S Lander; Todd R Golub; Stanley J Korsmeyer
Journal:  Nat Genet       Date:  2001-12-03       Impact factor: 38.330

6.  Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements.

Authors:  Shuichi Tsutsumi; Takeshi Taketani; Kunihiro Nishimura; Xijin Ge; Tomohiko Taki; Kanji Sugita; Eiichi Ishii; Ryoji Hanada; Misao Ohki; Hiroyuki Aburatani; Yasuhide Hayashi
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

7.  Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb.

Authors:  Nikla Emambokus; Alexandros Vegiopoulos; Ben Harman; Eric Jenkinson; Graham Anderson; Jon Frampton
Journal:  EMBO J       Date:  2003-09-01       Impact factor: 11.598

8.  Reduced proliferative capacity of hematopoietic stem cells deficient in Hoxb3 and Hoxb4.

Authors:  Jon Mar Björnsson; Nina Larsson; Ann C M Brun; Mattias Magnusson; Elisabet Andersson; Patrik Lundström; Jonas Larsson; Ewa Repetowska; Mats Ehinger; R Keith Humphries; Stefan Karlsson
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

9.  Molecular characterization of acute leukemias by use of microarray technology.

Authors:  Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
Journal:  Genes Chromosomes Cancer       Date:  2003-08       Impact factor: 5.006

10.  Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia.

Authors:  Bernard M Fine; Martin Stanulla; Martin Schrappe; Minh Ho; Susanne Viehmann; Jochen Harbott; Linda M Boxer
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

View more
  81 in total

1.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

2.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

3.  Meis1 maintains stemness signature in MLL-AF9 leukemia.

Authors:  Ashish R Kumar; Aaron L Sarver; Baolin Wu; John H Kersey
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

4.  Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Authors:  Chinavenmeni S Velu; Aditya Chaubey; James D Phelan; Shane R Horman; Mark Wunderlich; Monica L Guzman; Anil G Jegga; Nancy J Zeleznik-Le; Jianjun Chen; James C Mulloy; Jose A Cancelas; Craig T Jordan; Bruce J Aronow; Guido Marcucci; Balkrishen Bhat; Brian Gebelein; H Leighton Grimes
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

5.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

6.  Targeting acute myeloid leukemia by drug-induced c-MYB degradation.

Authors:  V Walf-Vorderwülbecke; K Pearce; T Brooks; M Hubank; M M van den Heuvel-Eibrink; C M Zwaan; S Adams; D Edwards; J Bartram; S Samarasinghe; P Ancliff; A Khwaja; N Goulden; G Williams; J de Boer; O Williams
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

7.  Where do the leukaemia relapses come from?

Authors:  Arndt Borkhardt
Journal:  J Mol Med (Berl)       Date:  2010-03       Impact factor: 4.599

Review 8.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

9.  Mechanisms of mixed-lineage leukemia.

Authors:  Andrew G Muntean
Journal:  Int J Hematol Oncol       Date:  2013-06-01

10.  Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia.

Authors:  Xi Jiang; Hao Huang; Zejuan Li; Yuanyuan Li; Xiao Wang; Sandeep Gurbuxani; Ping Chen; Chunjiang He; Dewen You; Shuodan Zhang; Jinhua Wang; Stephen Arnovitz; Abdel Elkahloun; Colles Price; Gia-Ming Hong; Haomin Ren; Rejani B Kunjamma; Mary Beth Neilly; Jonathan M Matthews; Mengyi Xu; Richard A Larson; Michelle M Le Beau; Robert K Slany; Paul P Liu; Jun Lu; Jiwang Zhang; Chuan He; Jianjun Chen
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.